Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) EBIT Margin (2017 - 2025)

Assembly Biosciences (ASMB) has 8 years of EBIT Margin data on record, last reported at 100.87% in Q3 2025.

  • For Q3 2025, EBIT Margin rose 5919.0% year-over-year to 100.87%; the TTM value through Sep 2025 reached 116.83%, up 4712.0%, while the annual FY2024 figure was 159.26%, 74324.0% up from the prior year.
  • EBIT Margin reached 100.87% in Q3 2025 per ASMB's latest filing, up from 115.24% in the prior quarter.
  • Across five years, EBIT Margin topped out at 100.87% in Q3 2025 and bottomed at 301.81% in Q3 2021.
  • Average EBIT Margin over 4 years is 160.44%, with a median of 156.75% recorded in 2024.
  • Peak YoY movement for EBIT Margin: crashed -29019bps in 2021, then surged 7992bps in 2025.
  • A 4-year view of EBIT Margin shows it stood at 301.81% in 2021, then soared by 42bps to 175.22% in 2023, then rose by 11bps to 156.75% in 2024, then soared by 36bps to 100.87% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 100.87% in Q3 2025, 115.24% in Q2 2025, and 105.54% in Q1 2025.